GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Korro Bio Inc (NAS:KRRO) » Definitions » EV-to-EBIT

Korro Bio (Korro Bio) EV-to-EBIT : -4.78 (As of May. 20, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Korro Bio EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Korro Bio's Enterprise Value is $403.97 Mil. Korro Bio's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-84.53 Mil. Therefore, Korro Bio's EV-to-EBIT for today is -4.78.

The historical rank and industry rank for Korro Bio's EV-to-EBIT or its related term are showing as below:

KRRO' s EV-to-EBIT Range Over the Past 10 Years
Min: -28.39   Med: 0   Max: 0
Current: -4.78

KRRO's EV-to-EBIT is ranked worse than
100% of 429 companies
in the Biotechnology industry
Industry Median: 9.96 vs KRRO: -4.78

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Korro Bio's Enterprise Value for the quarter that ended in Jun. 2023 was $0.00 Mil. Korro Bio's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-84.53 Mil. Korro Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was %.


Korro Bio EV-to-EBIT Historical Data

The historical data trend for Korro Bio's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Korro Bio EV-to-EBIT Chart

Korro Bio Annual Data
Trend Dec21 Dec22 Dec23
EV-to-EBIT
- - -2.97

Korro Bio Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT - - - - -2.97

Competitive Comparison of Korro Bio's EV-to-EBIT

For the Biotechnology subindustry, Korro Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Korro Bio's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Korro Bio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Korro Bio's EV-to-EBIT falls into.



Korro Bio EV-to-EBIT Calculation

Korro Bio's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=403.973/-84.534
=-4.78

Korro Bio's current Enterprise Value is $403.97 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Korro Bio's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-84.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Korro Bio  (NAS:KRRO) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Korro Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2023 ) =EBIT / Enterprise Value (Q: Jun. 2023 )
=-84.534/0
= %

Korro Bio's Enterprise Value for the quarter that ended in Jun. 2023 was $0.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Korro Bio's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-84.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Korro Bio EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Korro Bio's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Korro Bio (Korro Bio) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
One Kendall Square, Suite 6-401, Building 600-700, Cambridge, MA, USA, 02139
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
Executives
David L. Lucchino director, officer: President and CEO C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Rick Yang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Edward T Mathers 10 percent owner C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Nessan Bermingham director 890 WINTER STREET, WALTHAM MA 02451
Atlas Venture Associates Xi, Llc 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
New Enterprise Associates 17, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 17, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea 17 Gp, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Atlas Venture Fund Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Opportunity Fund Ii, L.p. 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity Ii, Llc 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity Ii, Lp 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Steve Colletti officer: Chief Scientific Officer C/O KORRO BIO, INC., ONE KENDALL SQUARE, BUILDING 600-700, CAMBRIDGE MA 02139
Shelby J. Walker officer: See Remarks C/O KORRO BIO, INC., ONE KENDALL SQUARE, BUILDING 600-700, CAMBRIDGE MA 02139

Korro Bio (Korro Bio) Headlines

From GuruFocus

Korro Announces $70 Million Private Placement

By Marketwired 04-18-2024